PEPTIDE PROTEIN RESEARCH LIMITED

Company Registration Number:
03801319 (England and Wales)

Unaudited abridged accounts for the year ended 31 July 2025

Period of accounts

Start date: 01 August 2024

End date: 31 July 2025

PEPTIDE PROTEIN RESEARCH LIMITED

Contents of the Financial Statements

for the Period Ended 31 July 2025

Balance sheet
Notes

PEPTIDE PROTEIN RESEARCH LIMITED

Balance sheet

As at 31 July 2025


Notes
2025
2024


£
£
Fixed assets
Tangible assets: 3 327,510 376,908
Total fixed assets: 327,510 376,908
Current assets
Stocks: 69,700 67,709
Debtors:   307,470 354,742
Cash at bank and in hand: 1,988,408 1,895,677
Total current assets: 2,365,578 2,318,128
Creditors: amounts falling due within one year:   (76,150) (69,353)
Net current assets (liabilities): 2,289,428 2,248,775
Total assets less current liabilities: 2,616,938 2,625,683
Total net assets (liabilities): 2,616,938 2,625,683
Capital and reserves
Called up share capital: 15 15
Profit and loss account: 2,616,923 2,625,668
Shareholders funds: 2,616,938 2,625,683

The notes form part of these financial statements

PEPTIDE PROTEIN RESEARCH LIMITED

Balance sheet statements

For the year ending 31 July 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 28 April 2026
and signed on behalf of the board by:

Name: DR M FARRIS
Status: Director

The notes form part of these financial statements

PEPTIDE PROTEIN RESEARCH LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

PEPTIDE PROTEIN RESEARCH LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2025

2. Employees

2025 2024
Average number of employees during the period 20 17

PEPTIDE PROTEIN RESEARCH LIMITED

Notes to the Financial Statements

for the Period Ended 31 July 2025

3. Tangible Assets

Total
Cost £
At 01 August 2024 1,702,476
Additions 32,480
At 31 July 2025 1,734,956
Depreciation
At 01 August 2024 1,325,568
Charge for year 81,878
At 31 July 2025 1,407,446
Net book value
At 31 July 2025 327,510
At 31 July 2024 376,908